Home » Topics » Immuno-oncology, BioWorld Science

Immuno-oncology, BioWorld Science
RSS

Biomira enters collaborative agreement, licenses two patents for cancer vaccine

Nov. 29, 1999

Preliminary survival data from single Maxamine site submitted to ASCO

Nov. 24, 1999

AAPS news: clinical pharmacokinetic analysis of B43-genistein in patients

Nov. 23, 1999

Novel prostate cancer therapy in development at Procyon detailed at international conference

Nov. 23, 1999

NY-ESO-1-derived peptides and their use in cancer therapy and diagnosis

Nov. 23, 1999

StressGen to codevelop HspE7 with NCI for HPV diseases

Nov. 17, 1999

First approval granted for Melacine melanoma therapeutic vaccine

Nov. 5, 1999

Maxamine in combination with IL-2 shows positive results in brain cancer model

Nov. 3, 1999

Celltech Chiroscience development partner files for FDA approval of AML treatment

Nov. 2, 1999

Abbott licenses development, marketing rights to Theragyn from Antisoma

Oct. 29, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 20, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 20, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...